IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
Press release content from Business Wire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Frederic Ors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Press release content from Business Wire. The AP news staff was not involved in its creation. IMV’s Lead Immunotherapy to be Investigated in Breast Cancer May 10, 2021 GMT DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--May 10, 2021-- IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that its lead compound, maveropepimut-S (DPX-Survivac) will be investigated in patients with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer. HR+/HER2- tumors represent an u...